nodes	percent_of_prediction	percent_of_DWPC	metapath
Penicillamine—SLCO1B1—Irinotecan—hematologic cancer	0.136	0.654	CbGbCtD
Penicillamine—SLCO1B1—Methotrexate—hematologic cancer	0.0719	0.346	CbGbCtD
Penicillamine—L-Cysteine—MGMT—hematologic cancer	0.00553	1	CrCbGaD
Penicillamine—SLCO1B1—Codeine and Morphine Metabolism—ABCC3—hematologic cancer	0.00104	0.112	CbGpPWpGaD
Penicillamine—SLCO1B1—Codeine and Morphine Metabolism—UGT1A1—hematologic cancer	0.000975	0.106	CbGpPWpGaD
Penicillamine—SLCO1B1—Irinotecan Pathway—UGT1A1—hematologic cancer	0.000623	0.0676	CbGpPWpGaD
Penicillamine—SLCO1B1—Recycling of bile acids and salts—ABCC3—hematologic cancer	0.000596	0.0646	CbGpPWpGaD
Penicillamine—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCC3—hematologic cancer	0.000568	0.0615	CbGpPWpGaD
Penicillamine—SLCO1B1—Irinotecan Pathway—ABCG2—hematologic cancer	0.000541	0.0586	CbGpPWpGaD
Penicillamine—SLCO1B1—Codeine and Morphine Metabolism—ABCB1—hematologic cancer	0.000528	0.0572	CbGpPWpGaD
Penicillamine—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—SLC35B2—hematologic cancer	0.000463	0.0502	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—ABCC3—hematologic cancer	0.000311	0.0338	CbGpPWpGaD
Penicillamine—SLCO1B1—Drug Induction of Bile Acid Pathway—ABCB1—hematologic cancer	0.000289	0.0313	CbGpPWpGaD
Penicillamine—SLCO1B1—Transport of organic anions—ALB—hematologic cancer	0.000256	0.0277	CbGpPWpGaD
Penicillamine—SLCO1B1—Recycling of bile acids and salts—ALB—hematologic cancer	0.00019	0.0206	CbGpPWpGaD
Penicillamine—Nausea—Lenalidomide—hematologic cancer	0.000151	0.000194	CcSEcCtD
Penicillamine—Urticaria—Mitoxantrone—hematologic cancer	0.00015	0.000193	CcSEcCtD
Penicillamine—Anorexia—Etoposide—hematologic cancer	0.00015	0.000192	CcSEcCtD
Penicillamine—Hypersensitivity—Carmustine—hematologic cancer	0.000149	0.000192	CcSEcCtD
Penicillamine—Diarrhoea—Thiotepa—hematologic cancer	0.000149	0.000192	CcSEcCtD
Penicillamine—Body temperature increased—Mitoxantrone—hematologic cancer	0.000149	0.000192	CcSEcCtD
Penicillamine—Body temperature increased—Irinotecan—hematologic cancer	0.000149	0.000192	CcSEcCtD
Penicillamine—Toxic epidermal necrolysis—Doxorubicin—hematologic cancer	0.000149	0.000192	CcSEcCtD
Penicillamine—Nausea—Hydroxyurea—hematologic cancer	0.000149	0.000192	CcSEcCtD
Penicillamine—Vomiting—Bortezomib—hematologic cancer	0.000149	0.000191	CcSEcCtD
Penicillamine—Decreased appetite—Cisplatin—hematologic cancer	0.000149	0.000191	CcSEcCtD
Penicillamine—Hypersensitivity—Alitretinoin—hematologic cancer	0.000148	0.00019	CcSEcCtD
Penicillamine—Vomiting—Bleomycin—hematologic cancer	0.000148	0.00019	CcSEcCtD
Penicillamine—Rash—Bortezomib—hematologic cancer	0.000148	0.00019	CcSEcCtD
Penicillamine—Dermatitis—Bortezomib—hematologic cancer	0.000148	0.00019	CcSEcCtD
Penicillamine—Pancytopenia—Epirubicin—hematologic cancer	0.000147	0.000189	CcSEcCtD
Penicillamine—Rash—Bleomycin—hematologic cancer	0.000147	0.000188	CcSEcCtD
Penicillamine—Dermatitis—Bleomycin—hematologic cancer	0.000146	0.000188	CcSEcCtD
Penicillamine—Hypersensitivity—Ifosfamide—hematologic cancer	0.000146	0.000188	CcSEcCtD
Penicillamine—Muscular weakness—Doxorubicin—hematologic cancer	0.000146	0.000188	CcSEcCtD
Penicillamine—Vomiting—Vinorelbine—hematologic cancer	0.000145	0.000187	CcSEcCtD
Penicillamine—Body temperature increased—Gemcitabine—hematologic cancer	0.000145	0.000187	CcSEcCtD
Penicillamine—Renal failure—Methotrexate—hematologic cancer	0.000145	0.000186	CcSEcCtD
Penicillamine—Diarrhoea—Thalidomide—hematologic cancer	0.000144	0.000186	CcSEcCtD
Penicillamine—Rash—Vinorelbine—hematologic cancer	0.000144	0.000185	CcSEcCtD
Penicillamine—Dermatitis—Vinorelbine—hematologic cancer	0.000144	0.000185	CcSEcCtD
Penicillamine—Stomatitis—Methotrexate—hematologic cancer	0.000144	0.000185	CcSEcCtD
Penicillamine—Angiopathy—Prednisone—hematologic cancer	0.000144	0.000185	CcSEcCtD
Penicillamine—Asthma—Doxorubicin—hematologic cancer	0.000143	0.000184	CcSEcCtD
Penicillamine—Hypersensitivity—Vincristine—hematologic cancer	0.000143	0.000183	CcSEcCtD
Penicillamine—Eosinophilia—Doxorubicin—hematologic cancer	0.000142	0.000182	CcSEcCtD
Penicillamine—Haematuria—Methotrexate—hematologic cancer	0.00014	0.000181	CcSEcCtD
Penicillamine—Pancreatitis—Doxorubicin—hematologic cancer	0.00014	0.00018	CcSEcCtD
Penicillamine—Alopecia—Prednisone—hematologic cancer	0.00014	0.00018	CcSEcCtD
Penicillamine—Hepatobiliary disease—Methotrexate—hematologic cancer	0.000139	0.000179	CcSEcCtD
Penicillamine—Nausea—Bortezomib—hematologic cancer	0.000139	0.000179	CcSEcCtD
Penicillamine—Hypersensitivity—Mitoxantrone—hematologic cancer	0.000139	0.000179	CcSEcCtD
Penicillamine—Hypersensitivity—Irinotecan—hematologic cancer	0.000139	0.000179	CcSEcCtD
Penicillamine—Vomiting—Thiotepa—hematologic cancer	0.000139	0.000179	CcSEcCtD
Penicillamine—Diarrhoea—Carmustine—hematologic cancer	0.000139	0.000178	CcSEcCtD
Penicillamine—Mental disorder—Prednisone—hematologic cancer	0.000139	0.000178	CcSEcCtD
Penicillamine—Nausea—Bleomycin—hematologic cancer	0.000138	0.000178	CcSEcCtD
Penicillamine—Rash—Thiotepa—hematologic cancer	0.000138	0.000177	CcSEcCtD
Penicillamine—Dermatitis—Thiotepa—hematologic cancer	0.000138	0.000177	CcSEcCtD
Penicillamine—Diarrhoea—Alitretinoin—hematologic cancer	0.000137	0.000177	CcSEcCtD
Penicillamine—Agranulocytosis—Methotrexate—hematologic cancer	0.000137	0.000177	CcSEcCtD
Penicillamine—Decreased appetite—Etoposide—hematologic cancer	0.000136	0.000175	CcSEcCtD
Penicillamine—Diarrhoea—Ifosfamide—hematologic cancer	0.000136	0.000175	CcSEcCtD
Penicillamine—Pancytopenia—Doxorubicin—hematologic cancer	0.000136	0.000175	CcSEcCtD
Penicillamine—Nausea—Vinorelbine—hematologic cancer	0.000136	0.000175	CcSEcCtD
Penicillamine—Renal failure—Epirubicin—hematologic cancer	0.000136	0.000174	CcSEcCtD
Penicillamine—Body temperature increased—Cisplatin—hematologic cancer	0.000135	0.000174	CcSEcCtD
Penicillamine—Neuropathy peripheral—Epirubicin—hematologic cancer	0.000135	0.000174	CcSEcCtD
Penicillamine—Stomatitis—Epirubicin—hematologic cancer	0.000134	0.000173	CcSEcCtD
Penicillamine—Vomiting—Thalidomide—hematologic cancer	0.000134	0.000173	CcSEcCtD
Penicillamine—Anxiety—Betamethasone—hematologic cancer	0.000134	0.000173	CcSEcCtD
Penicillamine—Anxiety—Dexamethasone—hematologic cancer	0.000134	0.000173	CcSEcCtD
Penicillamine—Rash—Thalidomide—hematologic cancer	0.000133	0.000171	CcSEcCtD
Penicillamine—Dermatitis—Thalidomide—hematologic cancer	0.000133	0.000171	CcSEcCtD
Penicillamine—Haemoglobin—Methotrexate—hematologic cancer	0.000133	0.000171	CcSEcCtD
Penicillamine—Diarrhoea—Vincristine—hematologic cancer	0.000132	0.00017	CcSEcCtD
Penicillamine—Haemorrhage—Methotrexate—hematologic cancer	0.000132	0.00017	CcSEcCtD
Penicillamine—Haematuria—Epirubicin—hematologic cancer	0.000131	0.000169	CcSEcCtD
Penicillamine—Urinary tract disorder—Methotrexate—hematologic cancer	0.000131	0.000168	CcSEcCtD
Penicillamine—Hepatobiliary disease—Epirubicin—hematologic cancer	0.00013	0.000168	CcSEcCtD
Penicillamine—Nausea—Thiotepa—hematologic cancer	0.00013	0.000167	CcSEcCtD
Penicillamine—Urethral disorder—Methotrexate—hematologic cancer	0.00013	0.000167	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Triamcinolone—hematologic cancer	0.00013	0.000167	CcSEcCtD
Penicillamine—Diarrhoea—Mitoxantrone—hematologic cancer	0.000129	0.000166	CcSEcCtD
Penicillamine—Diarrhoea—Irinotecan—hematologic cancer	0.000129	0.000166	CcSEcCtD
Penicillamine—Vomiting—Carmustine—hematologic cancer	0.000129	0.000166	CcSEcCtD
Penicillamine—Agranulocytosis—Epirubicin—hematologic cancer	0.000129	0.000165	CcSEcCtD
Penicillamine—Rash—Carmustine—hematologic cancer	0.000128	0.000164	CcSEcCtD
Penicillamine—Dermatitis—Carmustine—hematologic cancer	0.000128	0.000164	CcSEcCtD
Penicillamine—Vomiting—Alitretinoin—hematologic cancer	0.000128	0.000164	CcSEcCtD
Penicillamine—Anaemia—Prednisone—hematologic cancer	0.000127	0.000164	CcSEcCtD
Penicillamine—Rash—Alitretinoin—hematologic cancer	0.000127	0.000163	CcSEcCtD
Penicillamine—Agitation—Prednisone—hematologic cancer	0.000127	0.000163	CcSEcCtD
Penicillamine—Dermatitis—Alitretinoin—hematologic cancer	0.000127	0.000163	CcSEcCtD
Penicillamine—Thrombocytopenia—Dexamethasone—hematologic cancer	0.000126	0.000163	CcSEcCtD
Penicillamine—Thrombocytopenia—Betamethasone—hematologic cancer	0.000126	0.000163	CcSEcCtD
Penicillamine—Vomiting—Ifosfamide—hematologic cancer	0.000126	0.000162	CcSEcCtD
Penicillamine—Hypersensitivity—Cisplatin—hematologic cancer	0.000126	0.000162	CcSEcCtD
Penicillamine—Diarrhoea—Gemcitabine—hematologic cancer	0.000126	0.000162	CcSEcCtD
Penicillamine—Nausea—Thalidomide—hematologic cancer	0.000125	0.000161	CcSEcCtD
Penicillamine—Renal failure—Doxorubicin—hematologic cancer	0.000125	0.000161	CcSEcCtD
Penicillamine—Rash—Ifosfamide—hematologic cancer	0.000125	0.000161	CcSEcCtD
Penicillamine—Dermatitis—Ifosfamide—hematologic cancer	0.000125	0.000161	CcSEcCtD
Penicillamine—Neuropathy peripheral—Doxorubicin—hematologic cancer	0.000125	0.000161	CcSEcCtD
Penicillamine—Urticaria—Etoposide—hematologic cancer	0.000125	0.00016	CcSEcCtD
Penicillamine—Haemoglobin—Epirubicin—hematologic cancer	0.000124	0.00016	CcSEcCtD
Penicillamine—Stomatitis—Doxorubicin—hematologic cancer	0.000124	0.00016	CcSEcCtD
Penicillamine—Body temperature increased—Etoposide—hematologic cancer	0.000124	0.000159	CcSEcCtD
Penicillamine—Haemorrhage—Epirubicin—hematologic cancer	0.000124	0.000159	CcSEcCtD
Penicillamine—Tinnitus—Methotrexate—hematologic cancer	0.000123	0.000159	CcSEcCtD
Penicillamine—Vomiting—Vincristine—hematologic cancer	0.000123	0.000158	CcSEcCtD
Penicillamine—Anorexia—Betamethasone—hematologic cancer	0.000123	0.000158	CcSEcCtD
Penicillamine—Anorexia—Dexamethasone—hematologic cancer	0.000123	0.000158	CcSEcCtD
Penicillamine—Urticaria—Prednisolone—hematologic cancer	0.000123	0.000158	CcSEcCtD
Penicillamine—Urinary tract disorder—Epirubicin—hematologic cancer	0.000122	0.000157	CcSEcCtD
Penicillamine—Rash—Vincristine—hematologic cancer	0.000122	0.000157	CcSEcCtD
Penicillamine—Dermatitis—Vincristine—hematologic cancer	0.000122	0.000157	CcSEcCtD
Penicillamine—Haematuria—Doxorubicin—hematologic cancer	0.000122	0.000156	CcSEcCtD
Penicillamine—Urethral disorder—Epirubicin—hematologic cancer	0.000121	0.000156	CcSEcCtD
Penicillamine—Hepatobiliary disease—Doxorubicin—hematologic cancer	0.000121	0.000155	CcSEcCtD
Penicillamine—Nausea—Carmustine—hematologic cancer	0.00012	0.000155	CcSEcCtD
Penicillamine—Angiopathy—Methotrexate—hematologic cancer	0.00012	0.000154	CcSEcCtD
Penicillamine—Vomiting—Irinotecan—hematologic cancer	0.00012	0.000154	CcSEcCtD
Penicillamine—Vomiting—Mitoxantrone—hematologic cancer	0.00012	0.000154	CcSEcCtD
Penicillamine—Nausea—Alitretinoin—hematologic cancer	0.000119	0.000154	CcSEcCtD
Penicillamine—Agranulocytosis—Doxorubicin—hematologic cancer	0.000119	0.000153	CcSEcCtD
Penicillamine—Rash—Mitoxantrone—hematologic cancer	0.000119	0.000153	CcSEcCtD
Penicillamine—Rash—Irinotecan—hematologic cancer	0.000119	0.000153	CcSEcCtD
Penicillamine—Dermatitis—Mitoxantrone—hematologic cancer	0.000119	0.000153	CcSEcCtD
Penicillamine—Dermatitis—Irinotecan—hematologic cancer	0.000119	0.000153	CcSEcCtD
Penicillamine—Nausea—Ifosfamide—hematologic cancer	0.000118	0.000152	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Dexamethasone—hematologic cancer	0.000118	0.000151	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Betamethasone—hematologic cancer	0.000118	0.000151	CcSEcCtD
Penicillamine—Arthralgia—Prednisone—hematologic cancer	0.000117	0.000151	CcSEcCtD
Penicillamine—Diarrhoea—Cisplatin—hematologic cancer	0.000117	0.000151	CcSEcCtD
Penicillamine—Anxiety—Prednisone—hematologic cancer	0.000117	0.00015	CcSEcCtD
Penicillamine—Alopecia—Methotrexate—hematologic cancer	0.000117	0.00015	CcSEcCtD
Penicillamine—Vomiting—Gemcitabine—hematologic cancer	0.000117	0.00015	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Prednisone—hematologic cancer	0.000116	0.00015	CcSEcCtD
Penicillamine—Mental disorder—Methotrexate—hematologic cancer	0.000116	0.000149	CcSEcCtD
Penicillamine—Rash—Gemcitabine—hematologic cancer	0.000116	0.000149	CcSEcCtD
Penicillamine—Dermatitis—Gemcitabine—hematologic cancer	0.000116	0.000149	CcSEcCtD
Penicillamine—Hypersensitivity—Etoposide—hematologic cancer	0.000116	0.000149	CcSEcCtD
Penicillamine—Tinnitus—Epirubicin—hematologic cancer	0.000115	0.000148	CcSEcCtD
Penicillamine—Haemoglobin—Doxorubicin—hematologic cancer	0.000115	0.000148	CcSEcCtD
Penicillamine—Nausea—Vincristine—hematologic cancer	0.000115	0.000148	CcSEcCtD
Penicillamine—Haemorrhage—Doxorubicin—hematologic cancer	0.000115	0.000147	CcSEcCtD
Penicillamine—Hypersensitivity—Prednisolone—hematologic cancer	0.000114	0.000147	CcSEcCtD
Penicillamine—Urinary tract disorder—Doxorubicin—hematologic cancer	0.000113	0.000145	CcSEcCtD
Penicillamine—Urticaria—Triamcinolone—hematologic cancer	0.000113	0.000145	CcSEcCtD
Penicillamine—Dysgeusia—Methotrexate—hematologic cancer	0.000113	0.000145	CcSEcCtD
Penicillamine—Body temperature increased—Triamcinolone—hematologic cancer	0.000112	0.000145	CcSEcCtD
Penicillamine—Angiopathy—Epirubicin—hematologic cancer	0.000112	0.000144	CcSEcCtD
Penicillamine—Urethral disorder—Doxorubicin—hematologic cancer	0.000112	0.000144	CcSEcCtD
Penicillamine—Decreased appetite—Dexamethasone—hematologic cancer	0.000112	0.000144	CcSEcCtD
Penicillamine—Decreased appetite—Betamethasone—hematologic cancer	0.000112	0.000144	CcSEcCtD
Penicillamine—Nausea—Irinotecan—hematologic cancer	0.000112	0.000144	CcSEcCtD
Penicillamine—Nausea—Mitoxantrone—hematologic cancer	0.000112	0.000144	CcSEcCtD
Penicillamine—Alopecia—Epirubicin—hematologic cancer	0.000109	0.000141	CcSEcCtD
Penicillamine—Skin disorder—Prednisone—hematologic cancer	0.000109	0.00014	CcSEcCtD
Penicillamine—Nausea—Gemcitabine—hematologic cancer	0.000109	0.00014	CcSEcCtD
Penicillamine—Vomiting—Cisplatin—hematologic cancer	0.000109	0.00014	CcSEcCtD
Penicillamine—Mental disorder—Epirubicin—hematologic cancer	0.000108	0.000139	CcSEcCtD
Penicillamine—Rash—Cisplatin—hematologic cancer	0.000108	0.000139	CcSEcCtD
Penicillamine—Dermatitis—Cisplatin—hematologic cancer	0.000108	0.000139	CcSEcCtD
Penicillamine—Diarrhoea—Etoposide—hematologic cancer	0.000107	0.000138	CcSEcCtD
Penicillamine—Anorexia—Prednisone—hematologic cancer	0.000107	0.000138	CcSEcCtD
Penicillamine—Tinnitus—Doxorubicin—hematologic cancer	0.000107	0.000137	CcSEcCtD
Penicillamine—Anaemia—Methotrexate—hematologic cancer	0.000106	0.000137	CcSEcCtD
Penicillamine—Dysgeusia—Epirubicin—hematologic cancer	0.000105	0.000136	CcSEcCtD
Penicillamine—Hypersensitivity—Triamcinolone—hematologic cancer	0.000105	0.000135	CcSEcCtD
Penicillamine—Angiopathy—Doxorubicin—hematologic cancer	0.000104	0.000134	CcSEcCtD
Penicillamine—Leukopenia—Methotrexate—hematologic cancer	0.000103	0.000133	CcSEcCtD
Penicillamine—Urticaria—Betamethasone—hematologic cancer	0.000103	0.000132	CcSEcCtD
Penicillamine—Urticaria—Dexamethasone—hematologic cancer	0.000103	0.000132	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Prednisone—hematologic cancer	0.000102	0.000132	CcSEcCtD
Penicillamine—Body temperature increased—Dexamethasone—hematologic cancer	0.000102	0.000131	CcSEcCtD
Penicillamine—Body temperature increased—Betamethasone—hematologic cancer	0.000102	0.000131	CcSEcCtD
Penicillamine—Nausea—Cisplatin—hematologic cancer	0.000102	0.000131	CcSEcCtD
Penicillamine—Alopecia—Doxorubicin—hematologic cancer	0.000101	0.00013	CcSEcCtD
Penicillamine—Mental disorder—Doxorubicin—hematologic cancer	0.0001	0.000129	CcSEcCtD
Penicillamine—Vomiting—Etoposide—hematologic cancer	9.97e-05	0.000128	CcSEcCtD
Penicillamine—Anaemia—Epirubicin—hematologic cancer	9.96e-05	0.000128	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC35B2—hematologic cancer	9.94e-05	0.0108	CbGpPWpGaD
Penicillamine—SLCO1B1—Bile acid and bile salt metabolism—ALB—hematologic cancer	9.91e-05	0.0107	CbGpPWpGaD
Penicillamine—Agitation—Epirubicin—hematologic cancer	9.9e-05	0.000127	CcSEcCtD
Penicillamine—Rash—Etoposide—hematologic cancer	9.89e-05	0.000127	CcSEcCtD
Penicillamine—Dermatitis—Etoposide—hematologic cancer	9.88e-05	0.000127	CcSEcCtD
Penicillamine—Arthralgia—Methotrexate—hematologic cancer	9.8e-05	0.000126	CcSEcCtD
Penicillamine—Decreased appetite—Prednisone—hematologic cancer	9.77e-05	0.000126	CcSEcCtD
Penicillamine—Dysgeusia—Doxorubicin—hematologic cancer	9.76e-05	0.000126	CcSEcCtD
Penicillamine—Rash—Prednisolone—hematologic cancer	9.75e-05	0.000125	CcSEcCtD
Penicillamine—Dermatitis—Prednisolone—hematologic cancer	9.74e-05	0.000125	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Methotrexate—hematologic cancer	9.73e-05	0.000125	CcSEcCtD
Penicillamine—Leukopenia—Epirubicin—hematologic cancer	9.64e-05	0.000124	CcSEcCtD
Penicillamine—SLCO1B1—Transport of vitamins, nucleosides, and related molecules—ALB—hematologic cancer	9.49e-05	0.0103	CbGpPWpGaD
Penicillamine—Nausea—Etoposide—hematologic cancer	9.32e-05	0.00012	CcSEcCtD
Penicillamine—Anaemia—Doxorubicin—hematologic cancer	9.21e-05	0.000118	CcSEcCtD
Penicillamine—Thrombocytopenia—Methotrexate—hematologic cancer	9.2e-05	0.000118	CcSEcCtD
Penicillamine—Nausea—Prednisolone—hematologic cancer	9.19e-05	0.000118	CcSEcCtD
Penicillamine—Arthralgia—Epirubicin—hematologic cancer	9.17e-05	0.000118	CcSEcCtD
Penicillamine—Agitation—Doxorubicin—hematologic cancer	9.16e-05	0.000118	CcSEcCtD
Penicillamine—Anxiety—Epirubicin—hematologic cancer	9.14e-05	0.000118	CcSEcCtD
Penicillamine—Skin disorder—Methotrexate—hematologic cancer	9.13e-05	0.000117	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Epirubicin—hematologic cancer	9.11e-05	0.000117	CcSEcCtD
Penicillamine—Vomiting—Triamcinolone—hematologic cancer	9.05e-05	0.000116	CcSEcCtD
Penicillamine—Rash—Triamcinolone—hematologic cancer	8.97e-05	0.000115	CcSEcCtD
Penicillamine—Dermatitis—Triamcinolone—hematologic cancer	8.96e-05	0.000115	CcSEcCtD
Penicillamine—Anorexia—Methotrexate—hematologic cancer	8.96e-05	0.000115	CcSEcCtD
Penicillamine—Urticaria—Prednisone—hematologic cancer	8.93e-05	0.000115	CcSEcCtD
Penicillamine—Leukopenia—Doxorubicin—hematologic cancer	8.92e-05	0.000115	CcSEcCtD
Penicillamine—Body temperature increased—Prednisone—hematologic cancer	8.89e-05	0.000114	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC26A4—hematologic cancer	8.86e-05	0.0096	CbGpPWpGaD
Penicillamine—Diarrhoea—Betamethasone—hematologic cancer	8.83e-05	0.000114	CcSEcCtD
Penicillamine—Diarrhoea—Dexamethasone—hematologic cancer	8.83e-05	0.000114	CcSEcCtD
Penicillamine—Thrombocytopenia—Epirubicin—hematologic cancer	8.61e-05	0.000111	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Methotrexate—hematologic cancer	8.56e-05	0.00011	CcSEcCtD
Penicillamine—Skin disorder—Epirubicin—hematologic cancer	8.54e-05	0.00011	CcSEcCtD
Penicillamine—Arthralgia—Doxorubicin—hematologic cancer	8.49e-05	0.000109	CcSEcCtD
Penicillamine—Anxiety—Doxorubicin—hematologic cancer	8.46e-05	0.000109	CcSEcCtD
Penicillamine—Nausea—Triamcinolone—hematologic cancer	8.45e-05	0.000109	CcSEcCtD
Penicillamine—Unspecified disorder of skin and subcutaneous tissue—Doxorubicin—hematologic cancer	8.43e-05	0.000108	CcSEcCtD
Penicillamine—Anorexia—Epirubicin—hematologic cancer	8.38e-05	0.000108	CcSEcCtD
Penicillamine—Hypersensitivity—Prednisone—hematologic cancer	8.28e-05	0.000107	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PHYH—hematologic cancer	8.24e-05	0.00893	CbGpPWpGaD
Penicillamine—Vomiting—Betamethasone—hematologic cancer	8.21e-05	0.000106	CcSEcCtD
Penicillamine—Vomiting—Dexamethasone—hematologic cancer	8.21e-05	0.000106	CcSEcCtD
Penicillamine—Decreased appetite—Methotrexate—hematologic cancer	8.17e-05	0.000105	CcSEcCtD
Penicillamine—Rash—Betamethasone—hematologic cancer	8.14e-05	0.000105	CcSEcCtD
Penicillamine—Rash—Dexamethasone—hematologic cancer	8.14e-05	0.000105	CcSEcCtD
Penicillamine—Dermatitis—Betamethasone—hematologic cancer	8.13e-05	0.000105	CcSEcCtD
Penicillamine—Dermatitis—Dexamethasone—hematologic cancer	8.13e-05	0.000105	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Epirubicin—hematologic cancer	8.01e-05	0.000103	CcSEcCtD
Penicillamine—Thrombocytopenia—Doxorubicin—hematologic cancer	7.96e-05	0.000102	CcSEcCtD
Penicillamine—Skin disorder—Doxorubicin—hematologic cancer	7.9e-05	0.000102	CcSEcCtD
Penicillamine—Anorexia—Doxorubicin—hematologic cancer	7.75e-05	9.97e-05	CcSEcCtD
Penicillamine—Diarrhoea—Prednisone—hematologic cancer	7.69e-05	9.89e-05	CcSEcCtD
Penicillamine—Nausea—Betamethasone—hematologic cancer	7.67e-05	9.86e-05	CcSEcCtD
Penicillamine—Nausea—Dexamethasone—hematologic cancer	7.67e-05	9.86e-05	CcSEcCtD
Penicillamine—Decreased appetite—Epirubicin—hematologic cancer	7.64e-05	9.83e-05	CcSEcCtD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—SMPD3—hematologic cancer	7.54e-05	0.00817	CbGpPWpGaD
Penicillamine—Urticaria—Methotrexate—hematologic cancer	7.46e-05	9.6e-05	CcSEcCtD
Penicillamine—Body temperature increased—Methotrexate—hematologic cancer	7.43e-05	9.55e-05	CcSEcCtD
Penicillamine—Musculoskeletal discomfort—Doxorubicin—hematologic cancer	7.41e-05	9.53e-05	CcSEcCtD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—AQP9—hematologic cancer	7.17e-05	0.00777	CbGpPWpGaD
Penicillamine—Vomiting—Prednisone—hematologic cancer	7.15e-05	9.19e-05	CcSEcCtD
Penicillamine—Rash—Prednisone—hematologic cancer	7.09e-05	9.12e-05	CcSEcCtD
Penicillamine—Dermatitis—Prednisone—hematologic cancer	7.08e-05	9.11e-05	CcSEcCtD
Penicillamine—Decreased appetite—Doxorubicin—hematologic cancer	7.07e-05	9.1e-05	CcSEcCtD
Penicillamine—Urticaria—Epirubicin—hematologic cancer	6.98e-05	8.98e-05	CcSEcCtD
Penicillamine—Body temperature increased—Epirubicin—hematologic cancer	6.95e-05	8.94e-05	CcSEcCtD
Penicillamine—Hypersensitivity—Methotrexate—hematologic cancer	6.92e-05	8.9e-05	CcSEcCtD
Penicillamine—Nausea—Prednisone—hematologic cancer	6.68e-05	8.59e-05	CcSEcCtD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—FXYD6—hematologic cancer	6.66e-05	0.00722	CbGpPWpGaD
Penicillamine—Hypersensitivity—Epirubicin—hematologic cancer	6.48e-05	8.33e-05	CcSEcCtD
Penicillamine—Urticaria—Doxorubicin—hematologic cancer	6.46e-05	8.31e-05	CcSEcCtD
Penicillamine—Body temperature increased—Doxorubicin—hematologic cancer	6.43e-05	8.27e-05	CcSEcCtD
Penicillamine—Diarrhoea—Methotrexate—hematologic cancer	6.43e-05	8.27e-05	CcSEcCtD
Penicillamine—Diarrhoea—Epirubicin—hematologic cancer	6.02e-05	7.74e-05	CcSEcCtD
Penicillamine—Hypersensitivity—Doxorubicin—hematologic cancer	5.99e-05	7.71e-05	CcSEcCtD
Penicillamine—Vomiting—Methotrexate—hematologic cancer	5.97e-05	7.68e-05	CcSEcCtD
Penicillamine—Rash—Methotrexate—hematologic cancer	5.92e-05	7.62e-05	CcSEcCtD
Penicillamine—Dermatitis—Methotrexate—hematologic cancer	5.92e-05	7.61e-05	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—SLC22A1—hematologic cancer	5.86e-05	0.00635	CbGpPWpGaD
Penicillamine—Vomiting—Epirubicin—hematologic cancer	5.59e-05	7.19e-05	CcSEcCtD
Penicillamine—Nausea—Methotrexate—hematologic cancer	5.58e-05	7.18e-05	CcSEcCtD
Penicillamine—Diarrhoea—Doxorubicin—hematologic cancer	5.57e-05	7.16e-05	CcSEcCtD
Penicillamine—Rash—Epirubicin—hematologic cancer	5.54e-05	7.13e-05	CcSEcCtD
Penicillamine—Dermatitis—Epirubicin—hematologic cancer	5.54e-05	7.12e-05	CcSEcCtD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—NUP98—hematologic cancer	5.53e-05	0.00599	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—S100A10—hematologic cancer	5.43e-05	0.00589	CbGpPWpGaD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—NUP214—hematologic cancer	5.33e-05	0.00578	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—GBA—hematologic cancer	5.31e-05	0.00576	CbGpPWpGaD
Penicillamine—Nausea—Epirubicin—hematologic cancer	5.22e-05	6.72e-05	CcSEcCtD
Penicillamine—Vomiting—Doxorubicin—hematologic cancer	5.17e-05	6.65e-05	CcSEcCtD
Penicillamine—Rash—Doxorubicin—hematologic cancer	5.13e-05	6.6e-05	CcSEcCtD
Penicillamine—Dermatitis—Doxorubicin—hematologic cancer	5.12e-05	6.59e-05	CcSEcCtD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC35B2—hematologic cancer	5.05e-05	0.00547	CbGpPWpGaD
Penicillamine—Nausea—Doxorubicin—hematologic cancer	4.83e-05	6.21e-05	CcSEcCtD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ATP1B1—hematologic cancer	4.75e-05	0.00515	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC26A4—hematologic cancer	4.5e-05	0.00488	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—FHL2—hematologic cancer	4.33e-05	0.00469	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ANXA2—hematologic cancer	4.12e-05	0.00446	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ATP4A—hematologic cancer	4.12e-05	0.00446	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SGK1—hematologic cancer	4.12e-05	0.00446	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ARNTL—hematologic cancer	3.78e-05	0.0041	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—TUBB2A—hematologic cancer	3.71e-05	0.00402	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GMPS—hematologic cancer	3.67e-05	0.00398	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—FTCD—hematologic cancer	3.67e-05	0.00398	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PHYH—hematologic cancer	3.67e-05	0.00398	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR2—hematologic cancer	3.63e-05	0.00394	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—IDH1—hematologic cancer	3.46e-05	0.00375	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ABCC3—hematologic cancer	3.42e-05	0.00371	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SMPD3—hematologic cancer	3.36e-05	0.00364	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—SPHK1—hematologic cancer	3.35e-05	0.00363	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ABCC3—hematologic cancer	3.25e-05	0.00353	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CRABP1—hematologic cancer	3.13e-05	0.00339	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ALOX5—hematologic cancer	3.05e-05	0.00331	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—SLC22A1—hematologic cancer	2.98e-05	0.00323	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—B3GAT1—hematologic cancer	2.93e-05	0.00318	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ASNS—hematologic cancer	2.93e-05	0.00318	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—DCK—hematologic cancer	2.93e-05	0.00318	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOA3—hematologic cancer	2.87e-05	0.00311	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—NUP98—hematologic cancer	2.81e-05	0.00304	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HDC—hematologic cancer	2.78e-05	0.00302	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ADCY7—hematologic cancer	2.73e-05	0.00296	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—NUP214—hematologic cancer	2.71e-05	0.00294	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ABCG2—hematologic cancer	2.65e-05	0.00288	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—SDC1—hematologic cancer	2.59e-05	0.00281	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CDA—hematologic cancer	2.54e-05	0.00276	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PC—hematologic cancer	2.45e-05	0.00265	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SLC35B2—hematologic cancer	2.37e-05	0.00256	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GBA—hematologic cancer	2.37e-05	0.00256	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—TFRC—hematologic cancer	2.36e-05	0.00256	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MTAP—hematologic cancer	2.16e-05	0.00234	CbGpPWpGaD
Penicillamine—SLCO1B1—SLC-mediated transmembrane transport—ALB—hematologic cancer	2.04e-05	0.00221	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—CYCS—hematologic cancer	1.98e-05	0.00215	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—FHL2—hematologic cancer	1.93e-05	0.00209	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—AGRN—hematologic cancer	1.89e-05	0.00205	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HMMR—hematologic cancer	1.79e-05	0.00194	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—IDH2—hematologic cancer	1.79e-05	0.00194	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—NCOR1—hematologic cancer	1.69e-05	0.00183	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ARNTL—hematologic cancer	1.69e-05	0.00183	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ABCB1—hematologic cancer	1.66e-05	0.00179	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ACP5—hematologic cancer	1.64e-05	0.00178	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CA9—hematologic cancer	1.64e-05	0.00178	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NCOR2—hematologic cancer	1.62e-05	0.00175	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—IDH1—hematologic cancer	1.54e-05	0.00167	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ABCC3—hematologic cancer	1.52e-05	0.00165	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—TXN—hematologic cancer	1.52e-05	0.00165	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTO1—hematologic cancer	1.52e-05	0.00165	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SPHK1—hematologic cancer	1.49e-05	0.00162	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—UGT1A1—hematologic cancer	1.43e-05	0.00155	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SLC22A1—hematologic cancer	1.39e-05	0.00151	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CRABP1—hematologic cancer	1.39e-05	0.00151	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ALOX5—hematologic cancer	1.36e-05	0.00147	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NUP98—hematologic cancer	1.32e-05	0.00143	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ADCY7—hematologic cancer	1.28e-05	0.00138	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NCOA3—hematologic cancer	1.28e-05	0.00138	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NUP214—hematologic cancer	1.27e-05	0.00137	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CG—hematologic cancer	1.26e-05	0.00136	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MTR—hematologic cancer	1.24e-05	0.00135	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ABCG2—hematologic cancer	1.24e-05	0.00135	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ENO2—hematologic cancer	1.22e-05	0.00132	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTT1—hematologic cancer	1.18e-05	0.00128	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—CREBBP—hematologic cancer	1.16e-05	0.00126	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—SDC1—hematologic cancer	1.16e-05	0.00125	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—CREBBP—hematologic cancer	1.11e-05	0.0012	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CD—hematologic cancer	1.1e-05	0.0012	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—ALB—hematologic cancer	1.09e-05	0.00118	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3R1—hematologic cancer	1.04e-05	0.00113	CbGpPWpGaD
Penicillamine—SLCO1B1—Transmembrane transport of small molecules—ALB—hematologic cancer	1.04e-05	0.00112	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CD44—hematologic cancer	9.82e-06	0.00106	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NQO1—hematologic cancer	9.82e-06	0.00106	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CB—hematologic cancer	9.62e-06	0.00104	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CYCS—hematologic cancer	9.29e-06	0.00101	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—HSP90AA1—hematologic cancer	9.24e-06	0.001	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PTEN—hematologic cancer	8.31e-06	0.000901	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTP1—hematologic cancer	8.19e-06	0.000888	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—EP300—hematologic cancer	7.93e-06	0.000859	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ABCB1—hematologic cancer	7.76e-06	0.000841	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—NCOR1—hematologic cancer	7.53e-06	0.000816	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—GSTM1—hematologic cancer	7.53e-06	0.000816	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—MTHFR—hematologic cancer	6.65e-06	0.000721	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism of lipids and lipoproteins—PIK3CA—hematologic cancer	5.86e-06	0.000636	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CG—hematologic cancer	5.59e-06	0.000606	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—CREBBP—hematologic cancer	5.18e-06	0.000562	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CD—hematologic cancer	4.91e-06	0.000533	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—ALB—hematologic cancer	4.85e-06	0.000526	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3R1—hematologic cancer	4.64e-06	0.000503	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CB—hematologic cancer	4.28e-06	0.000464	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PTEN—hematologic cancer	3.7e-06	0.000401	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—EP300—hematologic cancer	3.53e-06	0.000383	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—PIK3CA—hematologic cancer	2.61e-06	0.000283	CbGpPWpGaD
Penicillamine—SLCO1B1—Metabolism—AKT1—hematologic cancer	2.13e-06	0.000231	CbGpPWpGaD
